Skip to main content
. 2018 May 15;9:1920. doi: 10.1038/s41467-018-04244-2

Fig. 6.

Fig. 6

Therapeutic efficacy of the DY131 ESRRG agonist in GC. a The indicated cells were treated with DY131 at the dose shown and colony formation assays were performed. AGS (b) and MKN28 (c) cells were treated with DY131 and then transfected with TCF4/LEF1 and used in a cell proliferation (b) and colony formation (c) assay. d After NCI-N87 cell implantation, DY131 or vehicle was intraperitoneally injected into mice every 3 days and the tumor volume was measured at the indicated time points (n = 5 per group). e Tumor volumes and weights were measured from sacrificed mice. f Immunohistochemical analysis of mouse samples. gk Organoids from GC patients were incubated with DY131 and TCF4/LEF1 or without for 72 h and then stained with EdU and Hoechst dye. g, k Proliferation from organoids was quantified using Edu staining. i qRT-PCR analysis of human organoid samples. Data represent the mean ± s.d. from three independent replicates. Student’s t-test was used to examine statistical significance (*p < 0.05, **p< 0.01, ***p< 0.005, ****p< 0.001)